Biological Role and Therapeutic Potential of IDH Mutations in Cancer
Top Cited Papers
Open Access
- 24 May 2018
- journal article
- review article
- Published by Elsevier BV in Cancer Cell
- Vol. 34 (2), 186-195
- https://doi.org/10.1016/j.ccell.2018.04.011
Abstract
No abstract availableKeywords
Funding Information
- NCI (R01CA140316)
- NINDS (R01NS096407)
This publication has 89 references indexed in Scilit:
- Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activationNature, 2012
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotypeNature, 2012
- IDH mutation impairs histone demethylation and results in a block to cell differentiationNature, 2012
- 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomasNature Medicine, 2012
- Tet1 and Tet2 Regulate 5-Hydroxymethylcytosine Production and Cell Lineage Specification in Mouse Embryonic Stem CellsCell Stem Cell, 2011
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent DioxygenasesCancer Cell, 2011
- IDH1 mutation identified in one human melanoma metastasis, but not correlated with metastases to the brainBiochemical and Biophysical Research Communications, 2010
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of GliomaCancer Cell, 2010
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-HydroxyglutarateCancer Cell, 2010
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009